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Abstract
Introduction Serum levels of C-reactive protein (CRP) seldom
reflect disease activity in systemic lupus erythematosus (SLE).
We have previously shown that autoantibodies against neo-
epitopes of CRP often occur in SLE, but that this does not
explain the modest CRP response seen in flares. However, we
have repeatedly found that anti-CRP levels parallel lupus
disease activity, with highest levels in patients with renal
involvement; thus, we aimed to study anti-CRP in a material of
well-characterized lupus nephritis patients.
Methods Thirty-eight patients with lupus nephritis were
included. Treatment with corticosteroids combined with
cyclophosphamide, mycophenolate mofetil or rituximab was
started after baseline kidney biopsy. A second biopsy was taken
after ≥ 6 months. Serum creatinine, cystatin C, complement,
anti-dsDNA, anti-CRP and urinalysis were done on both
occasions. Biopsies were evaluated regarding World Health
Organisation (WHO) class and indices of activity and chronicity.
Renal disease activity was estimated using the British Isles
Lupus Assessment Group (BILAG) index.
Results At baseline, 34/38 patients had renal BILAG-A; 4/38
had BILAG-B. Baseline biopsies showed WHO class III (n = 8),
IV (n = 19), III to IV/V (n = 3) or V (n = 8) nephritis. Seventeen
out of 38 patients were anti-CRP-positive at baseline, and six at
follow-up. Overall, anti-CRP levels had dropped at follow-up (P
< 0.0001) and anti-CRP levels correlated with renal BILAG (r =
0.29, P = 0.012). A positive anti-CRP test at baseline was
superior to anti-dsDNA and C1q in predicting poor response to
therapy as judged by renal BILAG. Baseline anti-CRP levels
correlated with renal biopsy activity (r = 0.33, P = 0.045), but
not with chronicity index. Anti-CRP levels were positively
correlated with anti-dsDNA (fluorescence-enhanced
immunoassay: r = 0.63, P = 0.0003; Crithidia luciliae
immunofluorescence microscopy test: r = 0.44, P < 0.0001),
and inversely with C3 (r = 0.35, P = 0.007) and C4 (r = 0.29, P
= 0.02), but not with C1q (r = 0.14, P = 0.24). No associations
with urinary components, creatinine, cystatin C or the glomerular
filtration rate were found.
Conclusions In the present study, we demonstrate a statistically
significant correlation between anti-CRP levels and
histopathological activity in lupus nephritis, whereas a baseline
positive anti-CRP test predicted poor response to therapy. Our
data also confirm previous findings of associations between
anti-CRP and disease activity. This indicates that anti-CRP
could be helpful to assess disease activity and response to
therapy in SLE nephritis, and highlights the hypothesis of a
pathogenetic role for anti-CRP antibodies in lupus nephritis.
Introduction
Systemic lupus erythematosus (SLE) is characterized by mul-
tiple organ involvement, by production of a wide range of anti-
nuclear antibodies and by the presence of immune complexes
in the inflamed organs [1]. Impaired clearance of cellular
debris by the reticuloendothelial system is considered a key
event in the initiation and maintenance of SLE. Autoantigens
escaping physiological clearance may thus become exces-
sively presented to the adaptive immune system, resulting in
loss of peripheral tolerance and occurrence of a multitude ofPage 1 of 9
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against dsDNA are frequently found both in serum and inflam-
matory lesions in glomerulonephritis [3]. The circulating levels
of anti-dsDNA often correlate with disease activity, and these
autoantibodies are presumed to be of pathogenetic impor-
tance in lupus nephritis [4-6].
The pentraxins constitute an evolutionarily conserved group of
proteins, which are expressed during infection, systemic
inflammation or tissue damage and participate in the acute
phase response in many species [7]. The pentraxin family
includes long pentraxins (such as pentraxin 3, produced by
mononuclear cells in response to lipopolysaccharides, IL-1β
and TNF) and the liver-derived short pentraxins C-reactive pro-
tein (CRP) and serum amyloid P component mainly generated
by stimulation with IL-6 [7]. Despite raised levels of IL-6 and
extensive systemic inflammation, serum CRP concentrations
typically remain low in lupus flares [8], although differences
between certain disease manifestations [9] and conflicting
data have been reported [10]. The novel in vitro finding that
IFNα mediates suppression of IL-6-induced CRP expression
in human hepatocytes, however, could possibly explain the
weak CRP response in SLE flares [11].
CRP has several biological functions that are related to affinity
for molecules exposed on bacteria and apoptotic cells/cell
debris, such as phosphorylcholine, nucleosomes, and ribonu-
cleoproteins (snRNPs), thereby resembling a primitive form of
a natural antibody [12]. In addition, like IgG class antibodies,
CRP interacts with cellular Fcγ receptors, thereby facilitating
the phagocytic clearance of circulating opsonized material.
Activation of the classical complement pathway is considered
one of the main physiological functions of CRP. In contrast to
IgG-mediated classical activation, however, CRP-mediated
activation appears to be essentially limited to the initial stages
involving C1 to C4, with less formation of the membrane attack
complex [13]. Furthermore, at sufficient concentrations, solu-
ble native CRP may prevent activation of the classical comple-
ment pathway on biological surfaces due to consumption of
soluble C1q without binding C2/C4 [14].
In line with its role as a scavenger of autoantigens from dead
or dying cells, single nucleotide polymorphisms of the CRP
gene have been found to associate with low baseline levels of
CRP, with production of antinuclear antibodies, and with
increased susceptibility to SLE [8]. Furthermore, in two murine
lupus models, subcutaneous CRP injections delayed the dis-
ease onset, reversed nephritis, and prolonged the survival of
the animals - indicating a preventive and disease-modifying
role for CRP in SLE [8,13]. Very recently, however, this finding
was contradicted by others [15].
The presence of autoantibodies against CRP in lupus was
originally described by Frank A Robey and coworkers in 1985
[16]. Later, Bell and colleagues reported a high frequency of
autoantibodies against a certain dissociated and tissue-bound
form of CRP, recognized as monomeric CRP (mCRP) in SLE,
and at lower prevalence rates in subacute cutaneous lupus
erythematosus and primary biliary cirrhosis [17]. Since then
several groups have confirmed the finding of IgG class autoan-
tibodies against monomeric CRP (anti-CRP) in SLE and in
some other rheumatic conditions [18-22]. In addition, the
presence of autoantibodies against pentraxin 3 was recently
shown in SLE patients [23,24].
In a series of papers, we have demonstrated the strong corre-
lations between anti-CRP antibody level and disease activity
as reflected by the SLE disease activity index, anti-dsDNA anti-
body levels, and complement levels [12]. The anti-CRP assay
has been shown to be antigen-specific [17], without false pos-
itive results due to the presence of immune complexes [19,25]
or antibodies to DNA or nucleosomes [26]. We have also con-
sistently found that most patients with raised anti-CRP anti-
body levels appear to have a disease phenotype with renal
involvement. The latter was recently confirmed by Tan and col-
leagues, who found elevated anti-CRP in SLE patients - where
the antibody levels paralleled disease activity, particularly in
individuals with lupus nephritis [27]. The authors also studied
renal histopathology and found that anti-CRP antibody levels
correlated with tubulointerstitial lesions and the chronicity
index, but not with the activity index [27]. The aim of the
present study was therefore to compare anti-CRP antibody
levels in well-characterized lupus nephritis patients and to
seek potential associations with histopathology, renal activity
and response to therapy.
Materials and methods
Patients
Thirty-eight patients meeting the 1982 American College of
Rheumatology classification criteria for SLE [28] were
included in the study. All patients had biopsy-proven active
lupus nephritis (during the period 1995 to 2006) and partici-
pated in a prospective control programme at the rheumatology
clinic of Karolinska University Hospital (Stockholm, Sweden).
Thirty-four of the 38 patients (89%) were women (mean age,
33.0 years; range, 19 to 61 years) and four patients were men
(mean age, 34.8 years; range, 18 to 50 years). Thirty-three out
of 38 patients (87%) were Caucasian. The mean duration of
SLE was 6.9 years (range, 0 to 34 years). At baseline, 27
patients displayed proliferative nephritis (World Health Organ-
isation (WHO) class III or IV), eight patients showed membra-
nous pattern (WHO class V), and biopsies in three patients
were classified as both proliferative and membranous.
The patients were treated in accordance with clinical routine
for lupus nephritis [29], including corticosteroids combined
with cyclophosphamide intravenously (n = 27) or orally (n = 1),
rituximab (n = 6), and mycophenolate mofetil (n = 3). One
patient was initially treated with mycophenolate mofetil, but
switched to intravenous cyclophosphamide after 3 months. AtPage 2 of 9
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ples and urinary samples were collected. Serum samples were
kept frozen at -70°C for future analyses. After induction ther-
apy (mean time, 8 months; range, 6 to 15 months), the patients
underwent a second renal biopsy and further clinical and lab-
oratory data were collected. Additional data are presented in
Table 1.
Renal histopathology
Renal biopsies were performed by percutaneous ultrasonog-
raphy-guided puncture in accordance with a standard proto-
col. The renal tissue obtained was staged according to the
WHO classification for lupus nephritis [30]. All biopsies were
evaluated by light microscopy, immunofluorescence and elec-
tron microscopy. The biopsies were graded according to a
standardized semiquantitative histological scoring protocol for
activity and chronicity indices [31].
Renal disease activity and response to therapy
Renal disease activity was estimated using the classical Brit-
ish Isles Lupus Assessment Group (BILAG) index [32]. An
improvement of at least two grades in the renal domain of
BILAG (that is, from A to C or from B to D) at follow-up was
required for the patient to be regarded as a responder. The
BILAG index was translated into numerical data for correlation
analyses (A = 9, B = 3, C = 1 and D = 0) as suggested by Dr
David A Isenberg, London (personal communication).
Laboratory and serological measures
Renal function was monitored by urinalysis (dip-slide proce-
dure), urinary sediment assessment, 24-hour urine albumin
excretion, serum creatinine, the glomerular filtration rate
assessed by urinary clearance of iohexol according to clinical
routine, and cystatin C (turbidimetry).
Analyses of complement component C1q were performed by
rocket electrophoresis using polyclonal rabbit anti-C1q
(DAKO, Glostrup, Denmark). Levels of C1q were expressed
as the percentage of the levels of healthy blood donors (nor-
mal range, 76 to 136%). C3 (normal range, 0.70 to 1.3 g/l)
and C4 (normal range, 0.13 to 0.32 g/l) were determined by
nephelometry.
Assessments of serum IgG anti-dsDNA antibodies were made
by the ImmunoCAP fluorescence-enhanced immunoassay
(Pharmacia, Uppsala, Sweden), normal range <15 IU/ml, and
by the Crithidia luciliae immunofluorescence microscopy test
(CLIFT) with cut-off titre 1:10.
Anti-C-reactive protein antibody assay
IgG anti-CRP antibodies were measured with an ELISA as
described previously [26]. To avoid systematic errors, samples
from patients and controls were always randomly mixed on the
microtitre plates and analysed on the same occasion. Anti-
CRP antibody levels were expressed as the percentage of a
positive reference sample from a SLE patient at flare repre-
senting 100 arbitrary units. No differences were apparent con-
sidering the groups of men and women in the control material.
To exclude the possibility of non-specific binding, each serum
was also tested in the same way on uncoated plates.
Statistics
Figures were prepared in GraphPad Prism (version 4.0;
GraphPad Software Inc., San Diego, CA, USA). Correlation
analyses were performed using Spearman's rank correlation
(SPSS for Windows version 15.0.0; SPSS Inc. (IBM), Chi-
cago, IL, USA), and differences between groups were calcu-
lated with the Wilcoxon signed rank test or the Mann-Whitney
U test (GraphPad). Response to therapy was compared by
chi-square analysis using StatCalc (Epi Info version 3.5.1;
Centers for Disease Control and Prevention, Atlanta, GA,
USA). Two-tailed P < 0.05 was considered significant.
Ethics
Informed consent was obtained from all subjects. The
research protocol was approved by the regional ethics com-
mittee in Stockholm.
Results
Anti-CRP antibody levels were determined at baseline and fol-
low-up in each of the 38 patients. The cut-off value for positive
reaction was set at 8 units, calculated from the 95th percentile
in 100 healthy blood donors (controls). As indicated in Table
1, 17 out of 38 patients (45%) were judged anti-CRP anti-
body-positive at baseline and six patients (16%) were positive
at follow-up. Overall, the anti-CRP antibody levels were signif-
icantly reduced at follow-up (P < 0.0001) (Figure 1).
Anti-CRP antibody levels were more efficiently reduced in
patients who responded to therapy as judged by renal histopa-
thology (data not shown), and baseline anti-CRP levels were
significantly higher (P = 0.0097) in patients who did not reach
a renal BILAG improvement of at least two grades (Figure 2).
Neither a baseline lowered C1q (relative risk = 1.58, 95%
confidence interval = 0.87 to 2.84) nor a positive anti-dsDNA
antibody test as judged by the CLIFT (relative risk = 1.18, 95%
confidence interval = 0.42 to 3.26) predicted response to
therapy, whereas a positive anti-CRP test did (relative risk =
2.16, 95% confidence interval = 1.20 to 3.89). Response to
therapy in relation to anti-CRP, adjusted for C1q and anti-
dsDNA antibody status, respectively, is illustrated in Tables 2
and 3. A positive anti-CRP test was thus associated with a
poor response to therapy, particularly in patients with normal
C1q levels and a positive anti-dsDNA antibody test (CLIFT).
Patients with proliferative nephritis (WHO class III or IV) had a
greater reduction of anti-CRP antibody levels compared with
patients with membranous (WHO class V) nephritis (Figure 3),
although this was not statistically significant (P = 0.08).Page 3 of 9
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Table 1
Clinical characteristics and laboratory data for patients
Baseline Follow-up
Anti-CRP-positive Anti-CRP-negative Mann-Whitney Anti-CRP-positive Anti-CRP-negative Mann-Whitney
Age (years) 30.5 (13.1) 35.0 (11.6) NS 27.0 (8.2) 35.1 (12.7) NS
Gender
Female 16 18 5 29
Male 1 3 1 3
Ethnicity
Caucasian 16 17 5 28
Iranian Caucasian 0 3 0 3
Iraqi Caucasian 0 1 0 1
Asian 1 0 1 0
Creatinine (μmol/l) 95.3 (43.3) 97.0 (51.0) NS 78.3 (9.6) 83 (46.2) NS
Albuminuria (g/day) 1.7 (1.4) 2.7 (2.3) NS 1.6 (1.3) 0.8 (0.9) NS
C3 (g/l) 0.47 (0.26) 0.57 (0.24) NS 0.85 (0.28) 0.80 (0.27) NS
C4 (g/l) 0.09 (0.06) 0.10 (0.05) NS 0.14 (0.03) 0.14 (0.07) NS
C1q (% of normal 
reference)
57.9 (37.3) 79.0 (36.7) NS 73.0 (32.4) 83.0 (28.1) NS
Anti-dsDNA-positive 16 18 3 21
CLIFT titre, median 200 25 P = 0.04 25 10 NS
Renal histopathology
Class I 0 0 0 1
Class II 0 0 1 13
Class III 1 7 1 2
Class IV 12 7 2 4
Class III to IV/V 1 2 0 2
Class V 3 5 2 10
Activity index 7.0 (3.1) 5.5 (3.5) NS 3.5 (2.0) 2.7 (3.2) NS
Chronicity index 2.3 (1.9) 1.4 (2.0) NS 2.7 (1.0) 2.7 (2.4) NS
BILAG index
A 14 20 1 5
B 3 1 4 14
C 0 0 0 8














Data presented as mean (standard deviation) or n. BILAG, British Isles Lupus Assessment Group; CLIFT, Crithidia luciliae immunofluorescence 
microscopy test; CRP, C-reactive protein; NS, not significant.
Available online http://arthritis-research.com/content/11/6/R188Of the 17 anti-CRP antibody-positive patients at baseline, 16
patients had received cyclophosphamide and two patients
received mycophenolate mofetil (one in combination with
cyclophosphamide). One individual increased dramatically in
anti-CRP, from 8 units at baseline to 214 units at follow-up.
This patient with WHO class IVc nephritis received cyclophos-
phamide intravenously, but did not respond to therapy and
was regarded as an outlier (not included in all analyses). All six
anti-CRP antibody-positive patients at follow-up were positive
also at baseline, and all had received cyclophosphamide intra-
venously as induction therapy. Five of these six patients did not
respond to therapy as judged by renal histopathology; one
patient switched from WHO class IVb to a IIa pattern, but the
remaining five patients had a similar or worsened histopatho-
logic picture with increment in the chronicity index. Using the
BILAG index, the same five individuals with persistently raised
anti-CRP levels did not respond to therapy (renal BILAG
improvement ≥ 2 grades). In the whole material, no obvious
relation between anti-CRP antibody reduction and the type of
induction therapy was found. All six patients receiving rituxi-
mab were consistently anti-CRP-negative. As illustrated in Fig-
ure 4, anti-CRP antibody levels at baseline showed a
moderate but statistically significant positive correlation with
the renal biopsy activity index (r = 0.33, P = 0.045), whereas
the association at follow-up did not reach statistical signifi-
cance (r = 0.30, P = 0.061). Accumulated anti-CRP data
yielded an even stronger correlation with histopathological
activity (r = 0.37, P = 0.0017). No associations between anti-
CRP levels and the chronicity index were found (not shown).
Figure 5 shows the correlation between anti-CRP antibody
levels and the BILAG index (r = 0.29, P = 0.012); when solely
anti-CRP-positive samples were included, the coefficient was
slightly decreased (r = 0.20). Using only anti-CRP-positive/
anti-dsDNA-negative samples (as judged by the CLIFT), anti-
CRP levels were barely associated with renal BILAG, but the
number of observations here were small (r = 0.10). The corre-
lation between BILAG and anti-dsDNA antibodies was weaker
still, however, measured by the fluorescence-enhanced immu-
noassay (r = 0.04) as well as by the CLIFT (r = 0.14); when
anti-DNA-negative samples (CLIFT) were excluded, the coeffi-
cient was further decreased (r = 0.08). Looking at anti-CRP-
negative/anti-dsDNA-positive samples (CLIFT), anti-DNA was
not significantly associated with renal BILAG. On the other
hand, anti-CRP levels correlated with anti-dsDNA antibodies
as measured with fluorescence-enhanced immunoassay (r =
0.63, P = 0.0003) and the CLIFT (r = 0.44, P < 0.0001).
Inverse correlations between anti-CRP and C4 (r = 0.29, P =
0.02) as well as between anti-CRP and C3 (r = 0.35, P =
0.007) were observed, while the tendency to an inverse rela-
tion between anti-CRP and C1q was not significant (r = 0.14,
p = 0.24). No associations between anti-CRP and urinary
components, creatinine, cystatin C or the glomerular filtration
rate were found.
Discussion
In the present study, we demonstrate a moderate but statisti-
cally significant correlation between anti-CRP antibody levels
and renal biopsy activity index in lupus nephritis. Elevated
baseline levels of anti-CRP were also found to be predictive of
the therapeutic response as judged by renal BILAG at follow-
Figure 1
Anti-C-reactive protein antibody levels in systemic lupus erythematosus patients befor and after induction therap
patients before and after induction therapy. Anti-C-reactive protein 
(anti-CRP) antibody levels at baseline and follow-up in 37 systemic 
lupus erythematosus patients (outlier excluded). Paired data were ana-
lysed with the Wilcoxon signed rank test.
Figure 2
Baseline anti-C-reactive protein antibody levels in responders and non-responders to given h rapy
responders to given therapy. At baseline, there was a highly significant 
difference in anti-C-reactive protein (anti-CRP) antibody levels between 
patients that would respond (n = 16) and would not respond (n = 22) 
to therapy (analysed with Mann-Whitney U test). Response to therapy 
was defined as a renal British Isles Lupus Assessment Group improve-
ment ≥ 2 grades. The limitations extend down from the lowest value 
and up to the highest. Median value for responders was 4 units, and 
was 9 units for nonresponders. Boxes show the 25th to 75th percen-
tile, with median values marked inside.Page 5 of 9
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associations between anti-CRP and lupus disease activity as
assessed by common clinical and laboratory disease activity
measures, such as complement and anti-dsDNA levels.
Although the results of this descriptive study do not allow con-
clusions regarding nephritogenic properties of anti-CRP anti-
bodies, our data imply that anti-CRP antibody testing is a
useful tool to support the clinician's evaluation of disease
activity and response to therapy in lupus nephritis.
Distinction of disease activity from organ damage in SLE
remains a challenge. Indirect assessment of disease activity
such as the BILAG index has proven reliable and sensitive to
change [33], but it is time consuming and requires a deft cer-
tified clinician. Microscopic examination of a kidney biopsy,
with classification and estimation of indices of renal disease
activity and chronicity, today offers the best possibility to esti-
mate renal disease and its response to therapy. Biopsy is
costly and is associated with considerable risks for the patient,
however, and can therefore not be done ad infinitum. Labora-
tory variables such as circulating complement components
and anti-dsDNA antibodies can be helpful, but there is an
urgent need for additional reliable biomarkers of disease activ-
ity in SLE.
We have previously demonstrated that the occurrence of
autoantibodies against the tissue-based/monomeric CRP is a
common finding in SLE, particularly in patients with nephritis
[12], and that anti-CRP antibody levels correlate with SLE dis-
ease activity index, anti-dsDNA and complement components
[26]. These findings have been confirmed by several groups
[18,20-22], although not in a recent study by Kessel and col-
leagues [34]. According to our experience, the prevalence of
positive anti-CRP tests in SLE is 30 to 50% depending on dis-
ease activity and disease phenotype [19,25,26]. Since the
present study was limited to patients with lupus nephritis, the
prevalence of 45% positive anti-CRP antibody tests was
slightly below expectation. A higher prevalence rate was
reported by Bell and colleagues [17], whereas an appreciably
lower frequency was found by Shoenfeld and colleagues [22].
Apart from differences in patient selection and disease pheno-
type (that is, renal involvement), the diverging results in these
studies [18,20-22,27] may be due to differences in methodo-
logical details regarding anti-CRP antibody analysis. Contrast-
ing to most other studies, we refrain from the use of BSA to
block nonspecific IgG-binding in our anti-CRP antibody assay,
since serum antibodies to BSA (and other dietary proteins) are
common and may thus affect the results, regardless of
whether or not BSA is also included in the dilution buffer [35].
In a recent study by Tan and colleagues, positive correlations
were reported regarding anti-CRP antibody levels and chronic
Figure 3
Anti-C-reactive protein antibody levels in patients with proliferative ver-sus membranous lupus nephritis
sus membranous lupus nephritis. The levels of anti-C-reactive protein 
(anti-CRP) antibodies in the 26 patients with proliferative lupus nephri-
tis (World Health Organisation (WHO) class III/IV) were reduced to a 
greater extent than the eight patients with membranous lupus nephritis 
(WHO class V), although not statistically significant by the Mann-Whit-
ney U test (mean difference -8.3 vs. -1.1 units; P = 0.08). The vertical 
bars denote 95% confidence intervals. The outlier as well as the three 











































Renal BILAG response and the C1q/anti-CRP status demonstrated








Relative risk 3.14 (1.14 to 8.64)
Relative risks presented as chi-square (95% confidence interval). BILAG, British Isles Lupus Assessment Group; CRP, C-reactive protein.Page 6 of 9
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fibrosis and the chronicity index score, as well as regarding
disease activity assessments (that is, interstitial inflammation
and the SLE disease activity index) [27]. In contrast to the cur-
rent study, however, anti-CRP levels were not associated with
the renal activity index [27]. Our previous findings [25,26], as
well as the results from the present study, support the notion
that anti-CRP primarily reflects disease activity rather than
chronicity, severity or organ damage. The connection with
renal involvement is clear cut, but seems to be stronger in
WHO class III or IV than in membranous nephritis (Figure 3).
In this context, very interestingly, the presence of surface-
bound CRP has been demonstrated in the renal mesangium
and in glomerular capillary walls in specimens from patients
with lupus nephritis [36]. Since CRP was found to co-localize
with IgG, it is probable that this actually represent immune
complexes consisting of mCRP-anti-CRP. Further studies on
this interesting matter are underway.
During induction therapy, anti-CRP appears to behave simi-
larly to anti-dsDNA antibodies [26,37], but differently from
autoantibodies to SS-A/Ro and SS-B/La [25] and cardiolipin
(unpublished data). It has been hypothesized that anti-CRP
antibodies could play a role in lupus-related atherosclerosis
[38]. Although Figueredo and colleagues reported a weak
association between anti-CRP and anti-phospholipid antibod-
ies in SLE and non-SLE patients, however, they found no asso-
Table 3
Renal BILAG response and the anti-dsDNA/anti-CRP status demonstrated








Relative risk 3.00 (0.61 to 14.86)
Relative risks presented as chi-square (95% confidence interval). BILAG, British Isles Lupus Assessment Group; CRP, C-reactive protein.
Figure 4
Correlation between anti-C-reactive protein antibody levels and the renal histopathology ctivity index
renal histopathology activity index. Anti-C-reactive protein (anti-CRP) 
antibody levels at baseline correlated with the renal histopathology 
activity index according to the description by Austin and colleagues 
[31] (r = 0.33, P = 0.045), whereas the association at follow-up did not 
reach statistical significance (r = 0.30, P = 0.061). Correlations were 
analysed with Spearman's rank correlation. Anti-CRP levels in relation 
to the renal activity index are shown for baseline and follow-up samples, 
respectively, in 37 patients (outlier excluded).
Figure 5
Anti-C-reactive protein antibody level correlation with the renal British Isles Lupus Assessment Group ind x
Isles Lupus Assessment Group index. Anti-C-reactive protein (anti-
CRP) antibody levels correlated significantly with renal disease activity, 
as assessed by the classical British Isles Lupus Assessment Group 
(BILAG) index [32] using Spearman's rank correlation. Analysis from 
baseline and follow-up observations in 37 patients (outlier excluded).Page 7 of 9
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find, in our study of non-lupus patients with acute coronary
syndrome, any raised anti-CRP levels compared with the age-
matched controls that were anamnestically healthy and with-
out medication [39].
The growing interest for mCRP has highlighted its importance
in several disease states [40-42] and revealed bioactivities in
vitro and in vivo regarding elimination of immune complexes
[43], interaction with the complement system [14,44,45],
affinity for different Fcγ receptors [46], and proinflammatory
effects on platelets [47] and blood lipids [48]. Given all of
these mCRP-mediated biological effects, anti-CRP antibodies
may participate in the pathogenesis of lupus nephritis and sev-
eral mechanisms could be hypothesized. One possibility is
that native CRP dissociates into mCRP as it binds to nuclear
structures planted on the renal glomerular basement mem-
brane [6,49] due to impaired waste disposal [2]. Similar to
anti-dsDNA antibodies [50], anti-CRP antibodies may possibly
form in situ renal immune complexes, which initiate or amplify
the tissue inflammation [36]. Further, if the tissue microenvi-
ronment becomes acidic due to inflammation, CRP dissoci-
ates to mCRP, which may enhance binding of circulating
soluble immune complexes to phagocytic Fcγ receptors
[12,43] and constitute a vicious circle.
Conclusions
We have demonstrated a statistically significant correlation
between anti-CRP antibody levels and renal biopsy activity
index in patients with lupus nephritis. Anti-CRP antibody levels
have previously been found to correlate with disease activity,
but the present study is the first to show an association with
renal disease activity assessed with the BILAG index. In addi-
tion, the study suggests that a positive anti-CRP antibody test
is superior to anti-dsDNA antibodies and C1q in predicting
poor response to therapy in lupus nephritis as judged by renal
BILAG.
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